Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPA1 | O75762 | 2/20 | 0.57 |
| ▸ | NFE2L2 | Q16236 | 6/20 | 0.47 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.44 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.44 |
| ▸ | TTR | P02766 | 1/20 | 0.44 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.44 |
| ▸ | RELA | Q04206 | 1/20 | 0.44 |
| ▸ | AHR | P35869 | 1/20 | 0.41 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.38 |
| ▸ | MAOA | P21397 | 1/20 | 0.38 |
| ▸ | MAOB | P27338 | 1/20 | 0.38 |
| ▸ | DHFR | P00374 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15797144 | 0.86 | TRPA1 (0.68) | TRPA1NFE2L2PTGS1PTGS2TTR | |
| SCHEMBL15797145 | 0.86 | TRPA1 (0.68) | TRPA1NFE2L2PTGS1PTGS2TTR | |
| SCHEMBL17594612 | 0.80 | NFE2L2 (0.50) | TRPA1NFE2L2CYP19A1MAOAMAOB | |
| SCHEMBL31421960 | 0.80 | NFE2L2 (0.50) | TRPA1NFE2L2CYP19A1MAOAMAOB | |
| SCHEMBL30279756 | 0.80 | TRPA1 (0.73) | TRPA1NFE2L2PTGS1PTGS2TTR | |
| SCHEMBL717978 | 0.80 | TRPA1 (0.73) | TRPA1NFE2L2PTGS1PTGS2TTR | |
| SCHEMBL9743428 | 0.80 | TRPA1 (0.73) | TRPA1NFE2L2PTGS1PTGS2TTR | |
| SCHEMBL3374804 | 0.78 | NFE2L2 (0.48) | TRPA1NFE2L2CYP19A1MAOAMAOB | |
| SCHEMBL135419 | 0.77 | PTGS1 (0.58) | TRPA1NFE2L2PTGS1PTGS2TTR | |
| SCHEMBL5605568 | 0.77 | TRPA1 (0.57) | TRPA1NFE2L2PTGS1PTGS2TTR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8530512-B2 | Broad spectrum gram-positive antimicrobials and anthelmintics with efficacy against drug-resistant strains and Mycobacterium species | MONTE AARON P (US) | 2013-09-10 | — | — | US | disclosed |
| US-20110092578-A1 | Broad Spectrum Gram-Positive Antimicrobials and Anthelmintics with Efficacy Against Drug-Resistant Strains and Mycobacterium Species | MONTE AARON P | 2011-04-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110092578-A1 | Broad Spectrum Gram-Positive Antimicrobials and Anthelmintics with Efficacy Against Drug-Resistant Strains and Mycobacterium Species | ABCC1, H1-3, H1-2 | TRPA1 261/4885NFE2L2 2978/4885PTGS1 681/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.